Clinical Trial Update: Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating stereotactic radiosurgery with erlotinib for non-small cell lung cancer and brain metastases was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Lung Cancer, Metastatic Cancer | Phase 1 | Status: WITHDRAWN